Mucinous, endometrioid, and clear cell cancers are less common and have unique characteristics and treatments. Germ cell ...

Dr Emma Bolderson, from QUT's School of Biomedical Sciences, has received a $460,552 grant from the Ovarian Cancer Research ...

of Northwestern University as a second site in a clinical trial combining the Company’s proprietary compound LB-100 with GSK’s Dostarlimab to treat ovarian clear cell cancer. Emily M.

Lurie Comprehensive Cancer Center (Lurie Cancer Center) of Northwestern University as a second site in a clinical trial combining the Company’s proprietary compound LB-100 with GSK’s Dostarlimab to ...

Lurie Comprehensive Cancer Center (Lurie Cancer Center) of Northwestern University as a second site in a clinical trial combining the Company's proprietary compound LB-100 with GSK's Dostarlimab to ...

Antibody-drug conjugates and their development remains a central theme in ongoing research within the realm of ovarian cancer ...

Dual checkpoint inhibitors led to longer overall survival in patients with high-risk endometrial cancer who displayed ...

Research has shed light on how a new type of antibody treatment reactivates patients' immune cells to fight ovarian cancer.